Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Akebia Therapeutics (AKBA) Stock Price & Analysis
1,232 Followers
AKBA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.78 - $2.48
Previous Close$0.94
Volume1.78M
Average Volume (3M)3.34M
Market Cap
$196.12M
Enterprise Value$191.94M
Total Cash (Recent Filing)$41.96M
Total Debt (Recent Filing)$37.78M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 01, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding209,596,378
10 Day Avg. Volume2,280,832
30 Day Avg. Volume3,337,288
Standard Deviation0.31
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.68
Price to Sales (P/S)0.98
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.11
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-21.93
Forecast
1Y Price Target
$4.00Price Target Upside327.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Akebia Therapeutics News
PremiumCompany Announcements
Akebia Therapeutics Welcomes New CFO and Financial Strategist
Ownership Overview
5.77% Insiders
8.94% Mutual Funds
16.23% Other Institutional Investors
69.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.78 and its highest was $2.48 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 25 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on May 09, 2024. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.072 by -$0.018.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -$0.04.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 209,596,370 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.072. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Deerfield Management Company, LP. It holds Akebia Therapeutics’s shares valued at 86K.
---
Akebia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (327.49% Upside)
$4.00 (327.49% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 62.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.56%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AKBA Earnings Call
Q1 2024
0:00 / 0:00
---
AKBA Stock 12 Month Forecast
Average Price Target
$4.00
▲(327.49% Upside)
Technical Analysis
Best Analysts Covering AKBA
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-40.98%
reiterated a buy rating 3 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -40.98% per trade.
---